ZIMV241220P30000
- 0.00
- 0.000.00%
ZimVie Newsroom
ZimVie Inc (ZIMV) Gets a Sell From Barclays
Earnings Call: ZimVie Reports Steady Growth and Improved Margins in Q3
Needham Maintains ZimVie(ZIMV.US) With Buy Rating, Maintains Target Price $23
ZimVie (ZIMV) Q3 2024 Earnings Call Transcript
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript Summary
ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript
Earnings Flash (ZIMV) ZIMVIE Reports Q3 Revenue $103.2M
Express News | ZimVie Inc -Sees FY Net Sales $450 Mln to $455 Mln
ZimVie | 10-Q: Q3 2024 Earnings Report
ZimVie | 8-K: ZimVie Reports Third Quarter 2024 Financial Results
GUIDANCE: (ZIMV) ZIMVIE Expects Fiscal Year 2024 EPS Range $0.57 - $0.62
Express News | ZimVie Q3 Adjusted Net Income USD 3.3 Million
Express News | ZimVie Q3 Adjusted EPS USD 0.12
Express News | ZimVie Q3 Adjusted Ebitda USD 13.1 Million
Press Release: ZimVie Reports Third Quarter 2024 Financial Results
ZimVie to Present at the UBS Global Healthcare Conference
Uncovering Potential: ZimVie's Earnings Preview
Earnings Preview: ZimVie to Report Financial Results Post-market on October 30
$ZimVie(ZIMV.US)$ is scheduled to release its financial results post-market on October 30 ET. Earnings PreviewAnalysts estimate $ZimVie(ZIMV.US)$ to post revenue of USD101.40M for 2024Q3, EPS is
ZimVie to Report Third Quarter Financial Results on October 30, 2024
Global Dental Implant Market Report and Company Analysis 2024-2032 Featuring Danaher, Dentsply Sirona, Institut Straumann, Zimmer Biomet, Kyocera, Henry Schein, Biocon, and Osstem Implant - ResearchAndMarkets.com